Smoothbore recall and AIFA registry updates: two kinds of access friction on one day

What happened

On 6 November 2026, Health Canada flagged a recall by Intersurgical of several lots of Smoothbore-based breathing systems in Canada. The recall follows market reports of soft connectors coming off the tubing. The company identified insufficient bonding solvent as the cause.

The records do not say which lots are affected or how many units were distributed. They also do not say whether any patient harm was reported, whether markets outside Canada are involved, or what remedy and timeline Intersurgical is offering. Those details matter for any commercial assessment and are not yet known from the material available.

The same day, Italy's medicines agency AIFA published a cluster of changes to its monitoring registries for oncology and haematology medicines. These are a different kind of event, but they show how access to products is governed after authorisation.

Why the recall matters commercially

A connector that detaches from breathing tubing is a mechanical failure in a product used to deliver gas to patients. The cause identified, insufficient bonding solvent, points to a manufacturing process issue rather than a design change. This is an inference from the stated cause, not something the records spell out.

For market access and procurement teams, the practical exposure is continuity of supply. Hospitals holding affected lots must quarantine or return them and find replacements. Where a supplier has framework agreements or tender commitments, a lot-level recall can create short-term substitution needs and questions about who bears the cost. The records say nothing about replacement arrangements, so teams should not assume any particular remedy.

This is not a pricing or reimbursement event in itself. It is a reminder that product quality events can disrupt access faster than any reimbursement decision.

The AIFA contrast: administrative access controls

AIFA monitoring registries are web-based systems. Prescribers use them to submit request and follow-up forms for reimbursed use of certain medicines under the national health service (SSN). When AIFA revises a registry, the forms clinicians must complete change, and that can affect how quickly a patient starts treatment.

The 6 November updates were varied. For Voranigo (vorasidenib), AIFA activated the registry and published clinical forms. Reimbursed use for grade 2 IDH-mutant astrocytoma or oligodendroglioma is possible from 6 November 2026. For Rybrevant (amivantamab), registries for two lung cancer indications now include subcutaneous schedules and their marketing authorisation numbers. A separate revision to the first-line EGFR exon 20 insertion registry adjusts when carboplatin-containing combinations are selected on the request form.

Lunsumio's registry for relapsed or refractory follicular lymphoma now includes subcutaneous dosing and new marketing authorisation numbers, following Determination PRES/1504/2026. Tevimbra's registries for gastric/GEJ adenocarcinoma and oesophageal squamous cell carcinoma add a new six-weekly dosing schedule and AIC codes, following Determination PRES/1512/2026. Imfinzi's neoadjuvant NSCLC registry gains a carboplatin-gemcitabine option in two forms. Enhertu's breast and gastric registries drop a block on treating patients with active, symptomatic or uncontrolled brain metastases.

Who is affected

On the device side, the records point to Canadian hospitals and distributors of Smoothbore-based breathing systems, plus Intersurgical's own commercial and quality teams. Exposure elsewhere is unconfirmed.

On the registry side, the updates mainly concern Italian prescribers, hospital pharmacies and the market access teams of the marketing authorisation holders. The new formulation and schedule entries (subcutaneous Rybrevant and Lunsumio, six-weekly Tevimbra) matter because a regimen missing from a registry can block or delay a reimbursed prescription. The records do not describe any actual delays, so this is a general operational risk rather than a reported problem.

The Enhertu change removes a restriction, widening the set of patients who can be entered into the registry. The records do not quantify the effect.

What to watch

For the recall, watch for Health Canada updates on lot scope, any extension to other jurisdictions, and Intersurgical's remedy. Teams with exposure should check whether their stock includes affected lots and what their supply contracts say about recalls.

For Italy, the key point is timing. Several of the changes took effect on 6 November 2026, the same day they were published. Teams should confirm that their products' regimens, codes and eligibility criteria are correctly reflected in the live registry forms. They should also check that field teams and hospital pharmacies know about the changes, particularly the carboplatin timing on Rybrevant and the new dosing schedules.